Preferred Label : SVN53-67/M57-KLH Peptide Vaccine;
NCIt synonyms : SurVaxM;
NCIt definition : A peptide vaccine containing a 15-mer peptide (DLAQMFFCFKELEGW), with C to M alteration
at amino acid position 57, derived from the anti-apoptosis protein survivin, and conjugated
with keyhole limpet hemocyanin (KLH), with potential immunopotentiating and antineoplastic
activities. Upon subcutaneous administration of SVN53-67/M57-KLH peptide vaccine,
this peptide is able to bind both HMC class I and II molecules and may activate the
immune system to mount a cytotoxic T-lymphocyte (CTL) as well as a T-helper cell response
against survivin-expressing cancer cells. This may result in decreased tumor cell
proliferation and ultimately tumor cell death. Survivin, a member of the inhibitor
of apoptosis (IAP) family, expressed during embryonic development while absent in
most normal adult cells, is upregulated in a variety of human cancers; its expression
in tumors is associated with a more aggressive phenotype, decreased survival, and
increased resistance to chemotherapy. KLH may enhance immune recognition and may promote
an enhanced response. As SVN53-67 is weakly immunogenic in humans, the M57 alteration
may lead to greater affinity towards HLA-A*0201 and thus an enhanced antitumor immune
response.;
UNII : HK7BJ56KSP;
CAS number : 2416847-76-0;
NCI Metathesaurus CUI : CL428171;
Origin ID : C95705;
UMLS CUI : C2987346;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
